{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:50:51Z","timestamp":1788587451481,"version":"build-2803163510"},"reference-count":78,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2189860","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T13:05:26Z","timestamp":1678453526000},"page":"411-421","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating the cost-utility of intravesical Bacillus Calmette-Gu\u00e9rin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-0473","authenticated-orcid":false,"given":"Kristin","family":"Grabe-Heyne","sequence":"first","affiliation":[{"name":"medac GmbH, Wedel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-9090","authenticated-orcid":false,"given":"Christof","family":"Henne","sequence":"additional","affiliation":[{"name":"medac GmbH, Wedel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Odeyemi","sequence":"additional","affiliation":[{"name":"Department of Health Professions, Health Economics and Outcomes Research, Manchester Metropolitan University, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-755X","authenticated-orcid":false,"given":"Johannes","family":"P\u00f6hlmann","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd, Harpenden, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-7614","authenticated-orcid":false,"given":"Waqas","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd, Harpenden, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd, Harpenden, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_3_8_5_1","unstructured":"Chang SS Boorjian SA Chou R et\u00a0al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline 2016. Amended 2020 [Internet]. 2020 [cited 2023 Feb 3]. Available from: https:\/\/www.auanet.org\/documents\/education\/clinical-guidance\/Non-Muscle-Invasive-Bladder-Cancer.pdf"},{"key":"e_1_3_8_6_1","unstructured":"NHS. Bladder cancer \u2013 Treatment [Internet]. 2017. [cited 2023 Feb 3]. Available from: https:\/\/www.nhs.uk\/conditions\/bladder-cancer\/treatment\/."},{"key":"e_1_3_8_7_1","unstructured":"NICE. Bladder cancer: diagnosis and management NICE guideline [NG2] [Internet]. 2015; [cited 2023 Mar 8]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng2"},{"key":"e_1_3_8_8_1","unstructured":"Leeds Teaching Hospitals. Urology bladder problems [Internet]. [cited 2023 Feb 3]. Available from: https:\/\/www.leedsth.nhs.uk\/a-z-of-services\/urology\/common-urological-conditions\/bladder-cancer\/."},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.58"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00481-1"},{"issue":"1","key":"e_1_3_8_11_1","first-page":"CD011935","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt S","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B, et\u00a0al. Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2020;1(1):CD011935.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.06.013"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.06.051"},{"key":"e_1_3_8_14_1","unstructured":"Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment: guidance for industry [Internet]. Silver Spring (MD): US Department of Health and Human Services Food and Drug Administration; 2018 [cited 2023 Feb 3]. Available from: https:\/\/www.fda.gov\/media\/101468\/download"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001633"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300409"},{"key":"e_1_3_8_18_1","volume-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer [Internet]","author":"Witjes J","year":"2022","unstructured":"Witjes J, Bruins H, Carri\u00f3n A, et\u00a0al. EAU guidelines on muscle-invasive and metastatic bladder cancer [Internet]. Amsterdam: European Association of Urology; 2022 [cited 2023 Mar 8]. Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Muscle-Invasive-And-Metastatic-Bladder-Cancer-2022.pdf"},{"key":"e_1_3_8_19_1","volume-title":"Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value: final report [Internet]","author":"ICER.","year":"2020","unstructured":"ICER. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value: final report [Internet]. Boston (MA): Institute for Clinical and Economic Review; 2020 [cited 2023 Mar 8]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_Bladder_Cancer_Final_Report_07292022.pdf"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001023"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2550-x"},{"key":"e_1_3_8_22_1","volume-title":"Guide to the methods of technology appraisal 2013: process and methods (PMG9) [Internet]","author":"NICE","year":"2013","unstructured":"NICE. Guide to the methods of technology appraisal 2013: process and methods (PMG9) [Internet]. London, Manchester: National Institute for Health and Care Excellence; 2013 [cited 2022 Dec 5]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.023"},{"key":"e_1_3_8_24_1","volume-title":"NICE health technology evaluations: the manual (PMG36) [Internet]","author":"NICE.","year":"2022","unstructured":"NICE. NICE health technology evaluations: the manual (PMG36) [Internet]. London (UK): National Institute for Health and Care Excellence; 2022 [cited 2023 Mar 8]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00937-z"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211721"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.05.018"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153797"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00167"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2021.2002435"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"e_1_3_8_32_1","unstructured":"ONS. National life tables \u2013 life expectancy in the UK: 2018 to 2020 [Internet]. Newport: Office for National Statistics; 2021 [cited 2022 Aug 30]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables"},{"key":"e_1_3_8_33_1","unstructured":"Public Health England. Cancer survival in England for patients diagnosed between 2014 and 2018 and followed up until 2019 [Internet]. GOV.UK. 2020 [cited 2023 Mar 8]. Available from: https:\/\/www.gov.uk\/government\/statistics\/cancer-survival-in-england-for-patients-diagnosed-between-2014-and-2018-and-followed-up-until-2019"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.12.004"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040284"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/codi.15848"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01407-y"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00239-w"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.05.001"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0580-7"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0375-7"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603326"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.03.049"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00308.x"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv224"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta24510"},{"key":"e_1_3_8_47_1","volume-title":"Cost-effectiveness analysis \u2013 botulinum toxin type a versus augmentation cystoplasty [Internet]","author":"National Clinical Guideline Centre (UK).","year":"2012","unstructured":"National Clinical Guideline Centre (UK). Cost-effectiveness analysis \u2013 botulinum toxin type a versus augmentation cystoplasty [Internet]. London: Royal College of Physicians; 2012 (Report No. 148). [cited 2023 Mar 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK132839\/"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1129-6"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24634"},{"key":"e_1_3_8_50_1","unstructured":"emc. OncoTICE powder for instillation fluid for intravesical use - summary of product characteristics (SmPC) [Internet]. 2021. [cited 2022 Jun 23]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1049"},{"key":"e_1_3_8_51_1","first-page":"E197","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a Markov microsimulation model","volume":"16","author":"Magee D","year":"2022","unstructured":"Magee D, Cheung D, Hird A, et\u00a0al. Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a Markov microsimulation model. Can Urol Assoc J. 2022;16: E197\u2013E204.","journal-title":"Can Urol Assoc J"},{"key":"e_1_3_8_52_1","volume-title":"2022\/23 National tariff payment system [Internet]","author":"NHS England and NHS Improvement","year":"2022","unstructured":"NHS England and NHS Improvement. 2022\/23 National tariff payment system [Internet]. London: NHS England and NHS Improvement; 2022 [cited 2022 May 26]. Available from: https:\/\/www.england.nhs.uk\/publication\/national-tariff-payment-system-documents-annexes-and-supporting-documents\/"},{"key":"e_1_3_8_53_1","unstructured":"Office for National Statistics. CPI INDEX: medical services [Internet]. 2022 [cited 2022 Jun 26]. Available from: https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/timeseries\/dkc3\/mm23"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_3_8_55_1","unstructured":"West Midlands Expert Advisory Group for Urological Cancer. Guidelines for the management of bladder cancer [Internet]. West Midlands Clinical Networks and Clinical Senate; 2019. [cited 2022 May 27]. Available from: https:\/\/www.england.nhs.uk\/mids-east\/wp-content\/uploads\/sites\/7\/2018\/05\/guidelines-for-the-management-of-bladder-cancer.pdf"},{"key":"e_1_3_8_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000463389"},{"key":"e_1_3_8_57_1","unstructured":"emc. Gemcitabine 38\u2009mg\/ml concentrate for solution for infusion - summary of product characteristics (SmPC) [Internet]. 2022 [cited 2022 May 30]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4483\/smpc"},{"key":"e_1_3_8_58_1","volume-title":"Guidelines for G-CSF use [Internet]","author":"West Midlands Cancer Alliance","year":"2021","unstructured":"West Midlands Cancer Alliance. Guidelines for G-CSF use [Internet]. Birmingham: West Midlands Cancer Alliance; 2021 [cited 2022 Nov 24]. Available from: https:\/\/wmcanceralliance.nhs.uk\/images\/WMCA_Guideline_for_Use_of_GCSF_Final_v1.0.pdf"},{"key":"e_1_3_8_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008933"},{"key":"e_1_3_8_60_1","unstructured":"Office for National Statistics. UK health indicators [Internet]. 2022 [cited 2022 Jun 27]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/datasets\/healthindicatorsfortheunitedkingdomanditsconstituentcountriesbasedonthe2013to2014europeanhealthinterviewsurveywave2"},{"key":"e_1_3_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14708"},{"key":"e_1_3_8_62_1","volume-title":"Unit costs of health and social care 2021","author":"Jones KC","year":"2021","unstructured":"Jones KC, Burns A. Unit costs of health and social care 2021. Kent (UK): Personal Social Services Research Unit; 2021."},{"key":"e_1_3_8_63_1","volume-title":"Treatment of high grade non-muscle invasive bladder carcinoma by standard number and dose of intravesical BCG instillations versus reduced number and dose of intravesical BCG instillations. A European Association of Urology Research Foundation randomised phase III clinical trial","author":"European Association Of Urology Research Foundation","year":"2021","unstructured":"European Association Of Urology Research Foundation T\u00fcrkeri LN, Babjuk MM. Treatment of high grade non-muscle invasive bladder carcinoma by standard number and dose of intravesical BCG instillations versus reduced number and dose of intravesical BCG instillations. A European Association of Urology Research Foundation randomised phase III clinical trial. Amsterdam: European Association of Urology Research Foundation; 2021."},{"key":"e_1_3_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066"},{"key":"e_1_3_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2019.11.003"},{"key":"e_1_3_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14105"},{"key":"e_1_3_8_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215276"},{"key":"e_1_3_8_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14490"},{"key":"e_1_3_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.06.018"},{"key":"e_1_3_8_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03908-x"},{"key":"e_1_3_8_71_1","doi-asserted-by":"publisher","DOI":"10.3310\/PLPU1526"},{"key":"e_1_3_8_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01665"},{"key":"e_1_3_8_73_1","unstructured":"Office for Health Improvement and Disparities. Cost utility analysis: health economic studies [Internet]. GOV.UK. 2020. [cited 2023 Mar 8]. Available from: https:\/\/www.gov.uk\/guidance\/cost-utility-analysis-health-economic-studies"},{"key":"e_1_3_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.018"},{"key":"e_1_3_8_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14888"},{"key":"e_1_3_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.05.027"},{"key":"e_1_3_8_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02637-9"},{"key":"e_1_3_8_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15008"},{"key":"e_1_3_8_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10391.x"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2189860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:04:17Z","timestamp":1701943457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2189860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2189860"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2189860","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}